API's
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients
API
BP/USP
C₃₁H₃₀N₆O₆
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]imidazole-5-carboxylate
144689-63-4
558.58 g/mol
Angiotensin II Receptor Blockers (ARBs).
| Appearance | White to off-white powder |
|---|---|
| Solubility | Poorly soluble in water; soluble in organic solvents like methanol and ethanol |
| Melting point | ~186–190 °C |
| pH | 3 to 5 |
Olmesartan medoxomil is a medication primarily used to treat high blood pressure (hypertension).
Olmesartan blocks the action of angiotensin II, a substance that tightens blood vessels. Blocking it widens vessels and lowers blood pressure.
| Attribute | Why Salius Pharma Is a Good Choice |
|---|---|
| Quality Certification | WHO GMP, ISO 9001:2015, FDA audited facilities |
| Affordability | Cost competitive generics |
| Export Experience | Proven track record globally |
When you order from Salius Pharma, you receive more than just a product — you receive a complete, professionally prepared package that meets international regulatory and quality expectations.
We ensure prompt and reliable shipping worldwide. Delivery times vary depending on destination, order volume, and regulatory requirements.
7 to 21 business days from dispatch, depending on your location.
Converted in body to active Olmesartan for better absorption.
Yes, in specific patients—monitor renal function.
May increase potassium; avoid supplements.
Looking to source Olmesartan Medoxomil or other high-quality pharmaceutical products?
We’re here to help.
Whether you need Active Pharmaceutical Ingredients (APIs), finished formulations, or regulatory support,
our team is ready to provide dependable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.